{"id":37670,"date":"2013-06-19T20:45:07","date_gmt":"2013-06-20T00:45:07","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=37670"},"modified":"2013-06-19T23:49:58","modified_gmt":"2013-06-20T03:49:58","slug":"business-as-usual-2","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2013\/06\/19\/business-as-usual-2\/","title":{"rendered":"business as usual&#8230;"},"content":{"rendered":"\n<p align=\"justify\">Dr. Nemeroff&#8217;s presentation in London felt like a  postcard from the past &#8211; a postcard from the time of Paxil Study 329 and TMAP, the  time of ghostwriters and chemical imbalance, the period when academic psychiatry and commercial enterprise wore each other like costumes at Mardi Gras bathed in the warm glow of future discovery just up ahead. it was a time when psychiatry had been freed from the shackles of speculation and transported into the light of a new century.<\/p>\n<p align=\"justify\">Yesterday, I watched&nbsp; Dr. Nemeroff&#8217;s <a target=\"_blank\" href=\"http:\/\/www.veomed.com\/grandrounds\/archive&#038;vid=817631&#038;gnr=824342\">Grand Rounds presentation at NYU<\/a> last year again. It was the part at the end about treatment implications that got to me. That story starts with a 2000 industry-funded non-placebo controlled comparison of a forgotten antidepressant and Cognitive Behavior Therapy or the combination. There had been innumerable earlier studies that showed that CBT plus antidepressant beat either one of them alone &#8211; so many that we used to joke that every new researcher must have to do a CBT\/Antidepressant study as a rite of passage. What was unique was the army of authors and the fact that the New England Journal didn&#8217;t have room for all the industry disclosures. The article launched editor Marcia Angell as an anti-COI activist.<\/p>\n<p align=\"justify\">I said <em>forgotten antidepressant<\/em> because by 2003 when Nemeroff&#8217;s paper was published, <strong><font color=\"#200020\">Nefazodone<\/font><\/strong> [<strong><font color=\"#200020\">Serzone&reg;<\/font><\/strong>] was being withdrawn from the market in Europe and stopped being sold in the US in 2004 because of hepatotoxicity. So it&#8217;s hard for me to see that 2000 study with its cadre of add-on authors as anything but business as usual in an era of junk science, and Dr. Nemeroff&#8217;s paper as an afterthought <span class=\"st\"> <\/span><span class=\"st\"><em><span class=\"st\">r\u00e9sum\u00e9-<\/span>churner<\/em>. Speaking of rites of passage, if a post-doc fellow had presented a secondary analysis of an industry funded, non-placebo controlled study to the Institute of Psychiatry at Kings College and made global pronouncements about how to treat chronically depressed patients based on the findings, I think he or she would have been shredded from the floor.<\/span><\/p>\n<div align=\"justify\">But exaggeration is not what this story is about. Making mountains out of molehills is the stuff of scientific presentations. There are, in fact, numerous examples in Dr. Nemeroff&#8217;s lecture all along. But the center of this story is about <em><strong><font color=\"#200020\">cheating<\/font><\/strong><\/em>. Dr. Nemeroff used the same slide that was in the 2003 article in full knowledge that it was wrong. It was Figure <strong><font color=\"#200020\">1A<\/font><\/strong> in that paper. Here&#8217;s the <a target=\"_blank\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1283482\/\">Erratum<\/a> published in 2005:<\/div>\n<blockquote>\n<div align=\"justify\">Results  of the analyses of variance comparing change in Hamilton  Rating Scale  for Depression scores as a function of treatment type and  early life  trauma histories as well as <font color=\"#990000\">Fig. 1A<\/font> reflect change relative to the first  week of treatment instead of baseline.  When change scores relative to  baseline are used, the interaction  effects between treatment type and  childhood trauma histories are not  statistically significant. This  discrepancy is due to marked changes in  depression scores during the  first week of treatment.<\/div>\n<\/blockquote>\n<div align=\"justify\">The data for this study had been pored over for multiple other papers by the time this article was written. It was submitted in 2003, before the sequence of exposures that lead to Dr.  Nemeroff&#8217;s being relieved of any number of positions. Frankly, this sounds  to me more like <em>fudging<\/em> than&nbsp; <em>error<\/em>, and I wonder how it came to light resulting in an <a target=\"_blank\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1283482\/\">Erratum<\/a>  report. We can&#8217;t know that nor can we know if it really was fudging instead of  just a mistake. But here&#8217;s what we can know. Using that slide in a  lecture in 2012 and probably again in 2013 cannot be an <em>error<\/em> &#8211;  an Erratum. If there&#8217;s anyone on the planet who should know about that  slide being discredited, it&#8217;s Dr. Charlie Nemeroff. The Erratum notice  goes on to say &#8211;<\/div>\n<blockquote>\n<div align=\"justify\">Note  that all analyses comparing the more conservative outcome measure of  remission as a function of treatment type and childhood trauma as well  as Fig. 1B are correct. Thus, consideration of treatment response  relative to baseline does not detect the effect of childhood trauma on  final remission, whereas consideration of final response relative to  first response does detect the effect.<\/div>\n<\/blockquote>\n<div align=\"justify\">&#8211; which implies that they stood by their conclusions even in the face of the <em>error<\/em> because there were other indicators that it was correct [like slide <strong><font color=\"#200020\">1B<\/font><\/strong>]. Maybe that&#8217;s right and maybe it&#8217;s not. But Dr. Nemeroff didn&#8217;t show us slide <strong><font color=\"#200020\">1B<\/font><\/strong>. He showed us slide <strong><font color=\"#200020\">1A<\/font><\/strong> &#8211; recolored but otherwise unchanged even though he knew it to be in error [2003 R, 2012 L]:<\/div>\n<div align=\"center\"><img decoding=\"async\" vspace=\"7\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/nefazodone-2.gif\" \/><\/div>\n<div align=\"justify\">If our hypothetical post doc fellow at the Maudsley did that, it would be considered a significant ethical violation and he or she would likely find themselves looking for another job. <\/div>\n<p align=\"justify\">Dr. Nemeroff is described as charismatic. I don&#8217;t know about that, but he&#8217;s certainly at home on a podium. All through his career, people have allowed him to get away with things they wouldn&#8217;t tolerate in others. They see him as bright, engaging, boyish, maybe an embellisher, but in an innocent sort of way. He&#8217;s used to being let off the hook. When he recommended treatments that he had a financial stake in without mentioning it in 2004, he got a hand slap. When he was exposed for <strike>writing<\/strike> signing on to a ghost written review of a vagal nerve stimulator with other coinvestors without mentioning his or their stake, he said it was a clerical error and gave up his editorship. When he was busted for unreported income from GSK while PI on a joint GSK NIMH grant and removed as chairman, he said he didn&#8217;t understand the rules and got another chairmanship within the year. All of those explanations were untrue, as were his defenses when he was exposed for a ghost-written textbook by POGO a year later. <\/p>\n<div align=\"justify\"><strong><font color=\"#200020\">So the point is that the slide 1A up there is a lie and he had to know it the second time around.<\/font><\/strong> The pattern of deceit is still business as usual. And to revive an oft used quote, &quot;<em>For every roach you see, there are a hundred hidden in the walls.<\/em>&quot; Psychiatry can neither tolerate nor survive another round of Dr. Nemeroff and friends&#8230;<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Nemeroff&#8217;s presentation in London felt like a postcard from the past &#8211; a postcard from the time of Paxil Study 329 and TMAP, the time of ghostwriters and chemical imbalance, the period when academic psychiatry and commercial enterprise wore each other like costumes at Mardi Gras bathed in the warm glow of future discovery [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-37670","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/37670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=37670"}],"version-history":[{"count":18,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/37670\/revisions"}],"predecessor-version":[{"id":42369,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/37670\/revisions\/42369"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=37670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=37670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=37670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}